Peptide Library / Detail
ACE-031
Half-life
Approximately 10–15 days (human PK, single-dose SC)
Delivery
Subcutaneous injection; historical clinical protocols dosed every 2–4 weeks.
Dosage
—
Research Use Only
All products listed are for laboratory research only — not for human consumption. By browsing, you acknowledge these terms.
Description
ACE-031 (ActRIIB-Fc Ligand Trap) is a recombinant fusion protein consisting of the extracellular domain of activin receptor type IIB (ActRIIB) linked to an IgG1 Fc fragment. It serves as a decoy receptor that binds myostatin (GDF8) and related ligands (e.g., activins), thereby reducing SMAD2/3 signaling to promote muscle and bone anabolism in research settings.
Usage
Used to study muscle-wasting disorders, sarcopenia/cachexia models, bone mass regulation, and downstream metabolic/functional outcomes (lean mass, strength, BMD).
Mechanism of Action
Ligand trap that sequesters myostatin and select activins from ActRIIA/B receptors, attenuating TGF-β/SMAD2/3 signaling; results include increased muscle protein synthesis/hypertrophy and bone accrual.
Benefits(3)
- Increases lean body mass and muscle volume in human and animal studies
- May improve functional measures (e.g., 6-minute walk trends in DMD studies)
- Associated increases in bone mineral density in some models
Side Effects(3)
- Epistaxis (nosebleeds) and telangiectasias reported in clinical studies
- Injection-site reactions (pain, pruritus, hematoma)
- Potential vascular effects linked to broader ligand binding (e.g., BMP9/10 cross-reactivity in class)